A new antibody has been discovered that could be developed as a generic influenza vaccine

U.S. team has discovered an antibody that "embedded" the surface protein of the flu virus to protect mice from a variety of influenza virus strains and is expected to be developed as a universal flu vaccine in the future.
H-protein (H-protein) and neural aninease (N-protein) are two proteins on the surface of influenza viruses that divide influenza viruses into different subsypes. The influenza vaccine currently developed is mainly targeted at hemocoagulants. In the winter of 2017, Ali Elibedi, an assistant professor of pathology and immunology at the University of Washington, found that a blood sample from a flu patient contained not only antibodies that target hemoglobin, but also antibodies that target other proteins.
Elbedi sent three of the unidentified-targeted antibodies to the Mount Sinai Icahn School of Medicine for testing, and Florian Kramer, a professor of microbiology at the institute, found that one of the antibodies, called "1G01," blocked the activity of almost all known neural anases on multiple influenza virus strains.
Kramer team infected laboratory mice with a lethal dose of the flu virus and found that the antibody could fight 12 tested strains of influenza, including three human influenza strains, bird flu and other strains that do not spread from person to person. Experiments found that all the mice survived, even after 72 hours of infection. By contrast, Duffy must be given the drug within 24 hours of the onsaic on the symptoms.
Iian Wilson, a structural biologist at the Scripps Institute in the United States, analyzed the structure of the antibody and found that it embedded a ring-like structure into the active part of the neuraminidase, preventing it from releasing new viral particles from the cell surface.
studies have shown that this antibody blocks only the active parts of neural anoenzyme, while the active sites between different influenza strains have little variation, so it is effective against a variety of influenza viruses. Researchers are currently designing new flu drugs and vaccines based on antibody 1G01.
study was published in the American journal Science. (Source: Xinhua News Agency, zhouzhou
related paper information: